FDA: Novo Nordisk failed to report deaths of weight-loss drug patients [USA TODAY]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: USA TODAY
The manufacturer of popular weight-loss drugs Ozempic and Wegovy, Novo Nordisk, is taking heat from the federal government for regularly failing to report potential side effects of its GLP-1 medications, including deaths. In a , the Food and Drug Administration cited five cases where patients taking the drugs experienced a stroke, considered suicide or died – one of them by suicide – all of which Novo Nordisk failed to report properly. Novo Nordisk's actions, the FDA wrote in its warning letter to the company, “suggest systemic failures with your surveillance, receipt, evaluation, and reporting” of potential side effects. Novo Nordisk representatives did not provide the specific number of patients affected when asked, but USA TODAY's analysis of FDA data shows a large spike in the company's submissions of side effect reports in July 2025, just a few months after the inspection. In one week alone, the company submitted nearly 11,000 reports of side effects involving semaglutid
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- The Donroe Doctrine Is Coming For Cuba [Seeking Alpha]Seeking Alpha
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- When generic versions of weight-loss drugs arrive, public plans should cover them, experts say [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Novo Nordisk Patent Loss In India Tests GLP 1 Valuation Story [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Just Opened the Door to Even Greater GLP-1 Growth [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/17/26 - Form 6-K
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website